Davos Alzheimer's Collaborative Healthcare System Preparedness to Increase Cognitive Assessment Rates for Older Adults

NARecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
Subjective Cognitive DeclineAlzheimer Dementia
Interventions
DIAGNOSTIC_TEST

Cognigram

Cognigram (previously known as the Cogstate Brief Battery) is a brief, computer-administered cognitive test battery requiring about 20-25 minutes for administration, consisting of four cognitive tasks to measure psychomotor function, attention, working memory, and learning and memory. Eisai owns the commercial rights for Cognigram and has kindly agreed to offer the required licenses for the present project free of charge. Digital cognitive testing will take place in the respective social and care centers on a tablet which is not connected to the internet. Testing will be performed pseudonymized and data from the cognitive tests will be downloaded regularly by the study team and added to the database at LMU hospital.

DIAGNOSTIC_TEST

Subjective cognitive decline questionnaire (SCD-Q)

The SCD-Q is a validated questionnaire assessing the presence of subjective cognitive deterioration in abilities such as memory, attention, language, and executive function. The scale includes 24 dichotomous questions (yes/no), evaluating decline in daily life during the last two years. The SCD-Q score ranges from 0 to 24, with higher scores indicating greater perceived cognitive change (cut-off classified as SCD equal or greater as 7).

DIAGNOSTIC_TEST

blood-based biomarkers

Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer. All test results (including the respective cut-off measurements for normal vs abnormal) will be forwarded directly to the participants' GPs. No further explanations and instructions will be provided to avoid any unwanted bias, and participants will only be informed about their results by their doctors. Roche has kindly offered to provide blood biomarker assays free of charge for the present project.

DIAGNOSTIC_TEST

ki:elements digital speech biomarker for cognition (ki:e SB-C)

The ki:elements digital speech biomarker for cognition (ki:e SB-C) can be collected remotely in fully automated telephone visits, taking 15 minutes to complete based on three specific assessments measuring learning and memory, processing speed, executive function, and language capabilities. The ki:e SB-C uses artificial intelligence and automatic speech analysis to process and transcribe speech, followed by an extraction of relevant features, combined into four subdomain and one global cognition score.

Trial Locations (1)

80336

RECRUITING

Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums, München

All Listed Sponsors
collaborator

ki:elements

UNKNOWN

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Eisai Limited

INDUSTRY

collaborator

Johanniter-Unfall-Hilfe e.V.

UNKNOWN

collaborator

University of Southern California

OTHER

lead

Ludwig-Maximilians - University of Munich

OTHER